Madras (Clodronate Disodium, Lidocaine Hydrochloride)

Madras combines a bisphosphonate and a local anesthetic to address bone‑related disorders and provide intramuscular analgesia.

• Osteoporosis: reduces osteoclast‑mediated bone resorption, helping maintain bone density.
• Paget disease of bone: normalizes abnormal bone remodeling and alleviates associated pain.
• Bone metastases: limits skeletal complications and provides local pain control.
• Local bone pain: delivers rapid analgesia through lidocaine‑mediated nerve blockade.

• Clodronate Disodium binds to hydroxyapatite in bone and is internalized by osteoclasts, where it disrupts the mevalonate pathway, leading to reduced bone resorption and osteoclast apoptosis. Lidocaine Hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing depolarization and transmission of pain signals, thereby producing a rapid local anesthetic effect at the injection site.

Madras may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the administration site.
• Erythema or swelling: localized redness or edema.
• Nausea: transient feeling of queasiness.
• Dizziness: brief episodes of light‑headedness.
• Headache: mild to moderate tension‑type headache.
• Flushing: temporary warmth or reddening of the skin.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with airway compromise.
• Hypocalcemia: significant drop in serum calcium levels.
• Renal impairment: acute kidney injury or worsening of pre‑existing renal disease.
• Cardiac arrhythmia: irregular heart rhythm potentially linked to lidocaine toxicity.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Osteonecrosis of the jaw: rare bone necrosis associated with bisphosphonate exposure.

Before prescribing Madras, clinicians should evaluate patient-specific factors and follow these precautions.

• Renal function: assess baseline kidney function and adjust use in severe impairment.
• Calcium levels: correct hypocalcemia prior to initiating therapy.
• Pregnancy: avoid unless the potential benefit justifies the risk to the fetus.
• Concomitant bisphosphonates: do not use with other bisphosphonate agents to prevent excess exposure.
• Allergy: contraindicated in patients with known hypersensitivity to clodronate or lidocaine.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Madras can interact with other medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid)

• Concurrent bisphosphonates: additive inhibition of bone resorption may increase toxicity.
• Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B): heightened risk of renal injury.
• Strong CYP450 inhibitors (e.g., ketoconazole, erythromycin): may raise lidocaine plasma concentrations.

Moderate Interactions (Monitor Closely)

• NSAIDs: may further compromise renal function when combined.